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Abstract
Polycyclic aromatic hydrocarbons are known carcinogens used in rodent experimental models. In this study, the 
carcinogen DMBA (7,12-dimethylbenzanthracene) was administered by gavage, diluted in corn oil, to female BALB / c 
mice at hebdomadary doses of 1 mg per animal for 1, 3, 6 or 9 weeks. Animals were weighed and monitored weekly until 
death. Remaining animals were euthanized at the age of 53 weeks. At necropsy, representative fragments of neoplasms 
were collected and routinely processed for histopathological analysis. Of all mice that received DMBA, 68.57% developed 
some type of tumor. Of the 70 mice treated with various doses of DMBA, 22 (31.43%) developed mammary tumors. 
The adenoacanthoma was the most commonly (18.75%) diagnosed histological type of breast cancer. Lung (15.71%), 
lymphoid tissue (11.43%), stomach (7.14%) and skin (2.86%) were also primary sites of tumor development. One third 
(33.33%) of the mice receiving 1 mg of DMBA developed lung cancer. Therefore, the administration of DMBA was 
shown to be an efficient model of carcinogenesis in mice, especially for the study of breast cancer, when using the 
highest dose, and lung, when using the lowest dose. Carcinogenesis models have been used for several purposes in 
cancer research. These results represent new facts for a classic carcinogenesis model.
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Resumo
Hidrocarbonetos policíclicos e aromáticos são carcinógenos usados em modelos experimentais em roedores. Neste 
estudo, o carcinógeno DMBA (7,12-dimetilbenzantraceno) foi administrado por gavagem, diluído em óleo de milho, 
para camundongos BALB/c em doses hebdomadárias de 1 mg por animal por 1, 3, 6 ou 9 semanas. Os animais foram 
pesados e monitorados semanalmente até a morte. Os animais remanescentes foram eutanasiados com a idade de 
53 semanas. Na necroscopia, fragmentos representativos das neoplasias foram colhidos e rotineiramente processados 
para exame histopatológico. De todos os animais que receberam DMBA, 68,57% desenvolveram algum tipo de tumor. 
Entre os 70 camundongos tratados com diferentes doses de DMBA, 22 (31,43%) desenvolveram neoplasias mamárias. 
O adenoacantoma foi o tumor mamário mais comumente diagnosticado (18,75%). Pulmões (15,71%), tecido linfoide 
(11,43%), estômago (7,14%) e pele (2,86%) foram também locais primários de desenvolvimento de neoplasias. Um 
terço (33,33%) dos camundongos que receberam 1 mg de DMBA desenvolveram neoplasias pulmonares. Portanto, 
a administração de DMBA foi considerada um modelo eficiente de carcinogênese em camundongos, especialmente 
para o estudo de neoplasias mamárias, quando a maior dose é utilizada, e de neoplasias pulmonares, quando utilizada 
a menor dose. Os modelos de carcinogênese química têm sido usados para diversos estudos na pesquisa em câncer, os 
resultados aqui apresentados mostram novos fatos para um modelo clássico de carcinogênese. 
Palavras-chave: Carcinogênese. DMBA. Camundongos. Neoplasias pulmonares. Neoplasias de mama. 
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Breast cancer is the second most common 
malignancy worldwide, second only to lung cancer 
and the first among women. Approximately, 22% 
of new cancer cases worldwide are breast cancer. 
Although breast cancer is considered to have a 
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relatively good prognosis if early diagnosed and 
treated appropriately, in Brazil, the median survival 
rate after five years is considered low compared with 
73% in developed countries (BRASIL, 2009). Due to 
the high frequency with which it reaches the human 
population, the scientific community has made many 
efforts in trying to diagnose this disease early and 
treat it more effectively, but many studies have yet 
to be developed in order to elucidate mechanisms, 
prognostic factors, treatment and predictive factors 
and thus, establish better control of breast cancer. In 
this sense, several research groups have attempted 
to develop experimental models of mammary 
carcinogenesis, so that various stages of this process 
are better understood and provide advances in 
prevention and cancer control. Several models of 
radiation carcinogenesis (WINCEWICZ et al., 2010) 
and by chemical agents (CHEUNG et al., 2010; JEE 
et al., 2011; MATSUOKA et al., 2010) have been 
presented, using different concentrations in order to 
induce the appearance of tumors, like studies with 
2-acetylaminofluorene (REIGH; STUART; FLOYD, 
1978), 3-methylcholanthrene (SHI et al., 2003), N- 
methyl-N-nitrosourea (MAFFINI et al., 2008) and 7,12- 
dimethylbenzanthracene (MEDINA, 1974). Currently. 
the most used carcinogens are DMBA and N-methyl-
N-nitrosourea (MEDINA; KITTRELL, 2005).
The main objective of this study was to establish 
a mouse model of mammary carcinogenesis so that 
it could be used in research to treat and prevent 
the development of breast tumors. The DMBA is a 
polycyclic aromatic hydrocarbon, a group that contains 
the majority of chemical carcinogens (CURRIER et al., 
2005) and requires biotransformation in the liver and 
mammary gland (TAMULSKI; MORREAL; DAO, 
1973). To obtain a greater induction of mammary 
gland tumors, the carcinogen is administered to young 
animals when these glands were undifferentiated, 
and then they were submitted to a high rate of cell 




 Ninety female BALB/c mice from the animal facility 
of the Department of Pathology, School of Veterinary 
Medicine and Animal Science of the University of São 
Paulo were used. The animals were kept in a room 
with ventilation (16-18 air changes / hour), relative 
humidity (45 – 65%), controlled temperature (20 – 
24°C) and light / dark cycle 12:12, given water and 
balanced diet ad libitum. The study has been approved 
by the Committee on Bioethics of the School of 
Veterinary Medicine and Animal Science of the 
University of São Paulo, Proc. nº. 1099/2007.
Carcinogenesis model
The carcinogen 7,12-dimethylbenzanthracene 
(Sigma-Aldrich, USA) was used, diluted in corn oil 
and administered by gavage to female BALB/c mice. 
Each animal received 1 mg per week until completing 
the total dose of 1, 3, 6 or 9 mg. The experiment began 
in the eighth week of life of animals, when they were 
weighed and examined by inspection and palpation 
weekly. Of the 90 animals, 20 were used as controls, 
receiving equally, by gavage, corn oil without the 
carcinogen. A total of 18, 15, 18 and 19 mice received, 
respectively, 1, 3, 6 or 9 mg of DMBA. All animals 
were euthanized when reaching inadequate physical 
condition, or at the end of 53 weeks (Figure 1). 
Figure 1 - DMBA carcinogenesis protocol used in the ex-
periment
Source: (AVANZO, 2011)
After being anesthetized with sodium pentobarbital 
(250 mg/kg), euthanasia was performed by section of the 
abdominal aorta. Immediately after euthanasia, necropsy 
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was performed, and representative fragments of tumors 
and organs (lungs, liver, kidneys, spleen, and stomach) 
were collected. These samples were fixed in methacarn 
(60% methanol, 30% chloroform and 10% acetic acid) 
and routinely processed for embedding in paraffin. 
Histological sections were stained with hematoxylin 
and eosin to be examined under a light microscope.
Histopathological study of tumors
All mouse tumors were classified according to IARC 
Scientific Publication no. 111 (TURUSOV; MOHR, 
1994).
Statistical analysis
Statistical analysis was performed using the 
GraphPad Prism (version 5.0, GraphPad Software Inc. 
USA). Two-way ANOVA was used to assess changes 
in body weight in relation to the rates during the 
experiment. To assess survival, Kaplan-Meier and 
long-rank test were used. The significance level was set 
at p < 0.05.
Results
Body weights
There was a significant variation in body weight 
(p < 0.0001) during the first 9 weeks of the 
carcinogenesis model (Figure 2). This significant 
change also occurred when doses were compared 
among them, and when the interaction of the doses 
and the time (weeks) was evaluated (p < 0.0001). 
Animals that received the dose of 9 mg presented the 
lowest body weight at the 9th week.
Survival
The longest survival time was observed at doses 
of 1 and 3 mg, with no difference in mortality rates 
between these two groups. The highest mortality rate 
was observed in the group exposed to 9 mg of DMBA. 
The first tumor appearance occurred at the 10th week in 
the 6 mg and at the 16th in the 9 mg group. Although 
the lesions appeared earlier in the first group (6 mg), 
the peak of mortality occurred earlier at 9 mg; the 
differences between these groups ranged from 6 to 14 
weeks. In both groups, the experiment was completed 
at 40 weeks. The survival differences were statistically 
significant when all groups were compared with 
control (p < 0.001) and between 1 and 6 mg (p < 0.001), 
3 and 6 mg (p = 0.0017) and 6 and 9 mg (p = 0.0034); 
the difference was not significant only between groups 
1 and 3 mg (p = 0.4414) (Figure 3). The control group 
remained without any physical or behavioral changes 
throughout the experiment.
Neoplasms diagnosed in BALB/c mice treated with 
different doses of DMBA
At necropsy, tumors were observed in breast, lung, 
lymphoid tissue, digestive tract and skin, varying 
according to the dose and locations (Table 1). One of 
Figure 2 - Body-weight variation along the experiment 
for the control group and the 1, 3, 6 and 9mg 
DMBA administration groups
Source: (AVANZO, 2011)
Figure 3 - Kaplan-Meier curve of the control group and 
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the animals had a tumor in the dorsal region near the 
column, developed hind limb paralysis, and was then 
euthanized.
During the experiment, among all mice that 
received DMBA, 68.6% developed some type of 
tumor. Of the 70 mice treated with various doses of 
DMBA, 22 (31.43%) developed mammary tumors. 
Adenoacanthoma was the most commonly diagnosed 
histological type of breast cancer. Lung (15.71%), 
lymphoid tissue (11.43%), stomach (7.14%) and skin 
(2.86%) were also primary sites of tumor development. 
One-third (33.33%) of the mice receiving 1 mg of 
DMBA developed lung cancer. 
All doses of DMBA used in this study were able to 
induce breast tumor, which began to appear at the 
10th week after the first dose of carcinogen. However, 
the vast majority of tumors appeared from the 16th 
week on.
Breast tumors were more frequent, with higher 
incidence in animals exposed to 6 and 9 mg and the 
non-breast occurred mainly in the final phase of the 
experiment. The lung was the second most frequent 
primary site, with higher incidence in the lowest dose. 
The histological classification of tumors observed is 
presented in table 2. 
Table 1 – Tumor incidence in different organs in control and DMBA-exposed groups – Sao Paulo – 2011
Neoplasias Control 1mg 3mg 6mg 9mg TOTAL
Breast 0.00%  11.11%  20.00%  38.90%  52.63% 22.23%
 (0/20) (2/18) (3/15) (7/18)  (1019)  (22/90)
Lung 0.00%  33.33%  26.70%  0.00%  5.16%  12.23%
 (0/20) (6/18) (4/15) (0/18) (1/19) (11/90)
Lymphoid tissue 0.00%  0.00%  13.30% 16.67% 15.80% 8.89%
 (0/20) (0/18)  (2/15) (3/18)  (3/19) (8/90)
Digestive tract 0.00%  0.00%  6.70%  5.56%  15.80% 5.56% 
 (0/20) (0/18) (1/15) (1/18)  (3/19) (5/90)
Skin 0.00%  0.00%  0.00%  0.00% 10.52% 2.23% 
 (0/20) (0/18) (0/15)  (0/18)  (2/19) (2/90)
TOTAL 0.00%  44.44%  66.67% 61.11% 100.00% 53.33% 
 (0/20) (8/18) (10/15) (11/18) (19/19) (48/90)
Table 2 –  Cancer incidence in different tumor types in 
control and DMBA-induced groups – Sao Paulo 
– 2011
Neoplasias  Number of tumors %
Breast   22 45.83
Adenoacanthoma 9 18.75
Cystic papillary adenocarcinoma 7 14.58
Carcinosarcoma 2 4.17
Fibroadenoma 1 2.08
Undifferentiated tumor 3 6.25
TOTAL 22 100.00
Lung  11 25.00
Lung papillary carcinoma 7 14.58
Mixed solid carcinoma 4 8.33
TOTAL 11 100.00
Digestive tract  5 10.42
Gastric squamous cell carcinoma 4 8.33
Esophagus squamous cell carcinoma 1 2.08
TOTAL 5 100.00
Lymphoid tissue - Lymphoma 8 16.67
Skin– keratoacanthoma 2 2.08
TOTAL 48 100.00
Among the histological types of tumors observed, 
adenoacanthoma was more frequent among 
breast, which included, besides, a cystic papillary 
adenocarcinoma, carcinosarcoma, undifferentiated 
tumor and fibroadenoma. In most of the animals, 
the tumors were highly infiltrative, with high mitotic 
activity, hemorrhage and extensive necrosis. Papillary 
carcinoma was the most frequent among lung tumors, 
which included, in addition, a solid mixed carcinoma 
and undifferentiated tumor. Squamous cell carcinoma 
was the only tumor type seen in the stomach. Images 
of tumor histological types observed are presented in 
figures 4 and 5.
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Tumor histological types
Figure 4 – Breast cancer developed in DMBA-induced groups. A. Adenoacanthoma, HE, bar=100 µm. 
B. Cystic papillary adenocarcinoma, HE, bar=200 µm C. Carcinosarcoma with cartilaginous 
metaplasia, HE, bar=100 µm. D. Carcinosarcoma with muscular invasion, HE, bar=100 µm. 
E. Fibroadenoma, HE, bar=200 µm. Undifferentiated tumor, HE, bar=100 µm
Source: (OLIVEIRA, 2012)
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Tumor histological types
Figure 5 – A. Lung papillary carcinoma, HE, bar=200 µm. B. Lung papillary carcinoma, HE, bar=100 µm. 
C. Gastric squamous cell carcinoma, HE, bar=200 µm D. Keratoacanthoma, HE, bar=100 µm 
E. Lymphoma, HE, bar=200 µm. F. Atypical mitosis (arrow), HE, bar=20 µm
 Source: (OLIVEIRA, 2012)
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Discussion
The main objective of this study was to establish a 
model for the study of mammary carcinogenesis in 
BALB/c mice. The carcinogen DMBA has been chosen 
because it was used in many studies of mammary 
carcinogenesis (MEDINA, 1974; HASLAM; BERN, 
1977; LANE et al., 1985; BARROS et al., 2004; 
CURRIER et al., 2005; MEDINA; KITTRELL, 2005; 
WIJNHOVEN et al., 2005; LU et al., 2006). Besides 
mammary tumors, in our study, neoplasms of diverse 
histogenesis have also been found, and we considered 
it important to report these findings, representing 
new facts for this carcinogenesis model.
All doses of DMBA used in this study were able to 
induce breast tumor, which began to appear at the 10th 
week after the first dose of carcinogen. However, the 
vast majority of tumors appeared from the 16th week. 
Likewise, other studies with the same strain of mice 
reported the appearance of tumors between the 10th and 
17th weeks (LANE et al., 1985; MEDINA; KITTRELL, 
2005). Two other studies reported, in mice, different 
incidences of mammary tumors with the dose of 6 mg 
of DMBA, 40% in one study (WIJNHOVEN et al., 
2005) and 75% in another (CURRIER et al., 2005). 
Higher incidence of mammary tumors were observed 
in rats, reaching 100% after 13 weeks of the beginning 
of administration (BARROS et al., 2004). In this study, 
we found 45.83% of breast cancers among all tumors, 
and the incidence was greater with increasing dose.
It has been noted that the development of mammary 
tumors in non-DMBA treated mice is common, 
mainly in the final phase of the study (MEDINA; 
KITTRELL, 2005); this aspect has also been shown 
in our study. Currier et al. (2005) reported non-
mammary neoplasms in DMBA model, including 
lung (15%), skin (10%) and lymphoid tissue (5%), 
although with lower incidence rates than those 
observed by us of 15.71%, 2.86% and 11.43%, 
respectively. It is known that diet has an influence on 
the development of tumors (EL-BAYOUMY et al., 
2006; MEDINA; LANE; SHEPHERD, 1983), as well 
as genetic characteristics of the strains involved and 
the climatic and environmental aspects associated 
with different countries, which may explain those 
differences.
The increased incidence and number of breast 
cancer was correlated with increasing dose of 
DMBA. Among the mechanisms that explain the 
development of mammary tumors by DMBA, 
there is the theory of activation of receptor/
transcription factor AhR (aryl hydrocarbon receptor 
/ transcription factor), a member of the family Per-
ARNT-Sim (PAS), of transcription factors that 
influence the development, circadian rhythms and 
hypoxia responses (TROMBINO et al., 2000). The 
administration of DMBA results in increased AhR 
activity and induction of CYP1A1, CYP1A2 and 
other enzymes involved in xenobiotic metabolism 
(HOFFMAN; GAY, 1981). These enzymes convert 
the DMBA in epoxide mutagenic intermediates, 
the 7-hydroxymethyl-12-methylbezantracene (7-
HMBA), 12-hydroxymethyl-7-metilbezantracene 
(12-HMBA) and 7,12-dimetilbezantracene that form 
DNA adducts. In the liver, the three metabolites above 
can be found, whereas in the mammary gland only 
monohydroxy (7- HMBA and 12-HMBA) are formed 
(TAMULSKI; MORREAL; DAO, 1973). These 
metabolites activate the AhR, mainly that complex 
with the heat-shock protein 90 (hsp90) and probably 
with other proteins; this has been only suggested but 
not described. When, for some reason, these two 
proteins dissociate, the AhR is free to translocate 
to the nucleus and dimerize with cofactor ARNT 
(aryl hydrocarbon receptor nuclear translocator), 
associating with specific transcription regulatory 
sequences in DNA. Once in the nucleus, they induce 
the expression of genes encoding growth factors and 
proto-oncogenes, including c-erb-2, c-myc, c-fos, 
c-Jun and H-ras (TROMBINO et al., 2000).
A higher expression of AhR, c-myc, cyclin D1 and 
Rb protein was found in DMBA-induced mammary 
tumors in mice. These proteins activate Wnt, NF-
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kB signaling pathway and the prolyl isomerase 
Pin-1 pathway, suggesting that tumor development 
is related to the cell growth and anti-apoptotic 
pathways. The crucial role of the P450 system seems 
clear, specifically the CYP1A1 and CYP1A2, and 
the transcription factor AhR in DMBA carcinogenic 
mechanism in all tissues. However, genes involved in 
each type of neoplasm may vary and require further 
study. Furthermore, the possible reversal dose-effect 
observed when lung tumors are compared with other 
histological types must be considered.
In our study, the most frequently diagnosed 
breast tumor was the adenoacanthoma, which was 
different from other studies in which the simple 
adenocarcinoma was the most prevalent, followed by 
adenoacanthoma (LANE et al., 1985). It is important 
to state that the adenoacanthoma is not a mammary 
histotype frequently found in humans. 
In order to study mammary carcinogenesis, doses 
of 3, 6 and 9 mg of DMBA are more suitable, since 
the 1 mg dose resulted in a low incidence of breast 
tumors. However, the choice of dose depends on 
the purpose of the study. Considering, for example, 
investigations into the chemopreventive activity of 
an active principle, the lower dose is recommended 
(SPORN; SUH, 2002).
We conclude that the DMBA resulted in an effective 
model of mammary carcinogenesis primarily, but 
also for stomach and lymphoid tissue neoplasms in 
higher doses (3, 6 and 9 mg), with incidence varying 
proportionally with increasing dose. In lower doses of 
1 and 3 mg, DMBA may be useful in a rodent model 
to study lung carcinogenesis.
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